Lecture Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Molecular Profiling and Decision Making in Breast Cancer: Defining Candidates for Gene Profiling

Release Date: November 26, 2008| Expiration Date: November 26, 2009
Nov 26, 2008, Online Learning Series Program 3

Lecture Overview

Molecular Profiling and Decision Making in Breast Cancer: A Continual Online Learning Series is designed to provide sustained online learning for oncologists and other health care providers involved in the diagnosis and treatment of breast cancer. In the area of molecular profiling, the recent emergence of commercially available gene profiling tools, coupled with their variable degree of benefit balanced against the short- and long-term effects of chemotherapy, creates a pressing educational need for clinicians. This educational activity is directed toward medical and surgical oncologists who counsel patients on therapeutic decisions following surgery for early-stage breast cancer. Other physicians, including pathologists, radiation oncologists, primary care physicians, and other health care providers, including nurses, pharmacists, and others who care for patients with breast cancer, are also invited to participate. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

At the conclusion of this activity, you should be able to:

  • Discuss the molecular heterogeneity of breast cancer and the relationship of gene-based molecular profiles to clinical outcomes
  • Compare and contrast different molecular profiling assays and their ability to provide accurate prognosis of patients with early-stage breast cancer
  • Apply molecular profiling to patient decision making in defined clinical scenarios
  • Describe the advantages and limitations of different molecular profiling assays and indications for participation in clinical trials designed to further evaluate their utility in decision making for early-stage breast cancer

Instructions for Participation

  • Read the following information before beginning the educational activity.
  • Complete the pre-test.
  • View and study all video presentations for the didactic portion and case discussions.
  • Complete the CME test.
  • CME test questions #2 and #5 must be answered correctly to receive a certificate.
  • Answer the evaluation questions.
  • After successful completion of the CME test and evaluation, you will receive your certificate of credit online.

Read all of the conditions in the Activity Terms box below. You must accept the Activity Terms in order to continue:

Disclosure Policy

It is the policy of Physicians' Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians' Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians' Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

These persons involved in the influence or control of content for the presentations from Molecular Profiling and Decision Making in Breast Cancer online learning series: Program #3 activity have disclosed the following relationship with the companies listed. The PER Scientific Content Team has no relevant financial relationships to disclose, unless noted below individually.

Matthew Ellis, MB, BChir, PhD, FRCP
Research Funding — AstraZeneca; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Taiho Pharmaceutical Company, LTD.
Paid Consultant— AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Speaker’s Bureau— AstraZeneca; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.

Lori Goldstein, MD
Research Funding — AstraZeneca; Bristol-Myers Squibb Company; Genomic Health, Inc.; GlaxoSmithKline; Johnson & Johnson; Merck & Co., Inc.; sanofi-aventis U.S.; Wyeth Pharmaceuticals
Paid Consultant — Amgen; AstraZeneca; Bayer Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Eisai Inc.; Eli Lilly and Company; Genentech, Inc.; Genomic Health, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Pharmion Corporation; sanofi-aventis U.S.

Charles Perou, PhD
Research Funding – Eli Lilly, Bristol-Myers Squibb Company, and Roche
Paid Consultant – Eli Lilly, Roche, and PharmaMar

Debu Tripathy, MD
No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is delineated by the faculty during the presentation. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Software Requirements

The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser.

If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Macintosh Users
Compatible Web browsers include

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the faculty and Physicians' Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

Privacy Policy

Physicians' Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2008 by Physicians' Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Molecular Profiling and Decision Making in Breast Cancer online learning series: Program #3
Physicians' Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@pergrouplp.com

Educational Grants

An educational grant for this activity was provided by:


  1. Agendia